the medical records of the enrolled patients, prescriptions were analyzed. Relevant patient information such as gender, age, and data concerning psychotropic prescribing patterns such as type of medication, route of administration, dose and frequency were collected and evaluated for prescription patterns and associated pharmaceutical care. RESULTS: Among the 60 bipolar patients enrolled during the study period from January 2011 to April 2011, majority of the patients (78.3%) were prescribed with antipsychotics, with olanzapine (25%) and resperidone (23.3%) being the two most common drugs followed by sedatives (73.3%), with clonazepam (38.3%) being the most common drug. A total of 68.3% of patients were prescribed with Lithium as the most common mood stabilizer. Among the patients (43.3%) prescribed with antidepressants, the combination of fluoxetin and amitriptyline was most common (23.3%) followed by fluoxetin alone (11.6%).Only 9 patients (15%) were prescribed with divalproex sodium, an anticonvulsant. CONCLUSIONS: This study showed that antipsychotics and sedatives were the two most commonly prescribed drugs in bipolar patients with lithium being the most widely prescribed mood stabilizer. The quality of pharmaceutical care is highly variable among patients with bipolar disorders, even in a specialty treatment setting.
OBJECTIVES:
The aim of the study is to investigate the use of medications prescribed to dementia patients in a secondary care hospital METHODS: A retrospective chart review method was performed in patients with diagnosis of dementia for the duration of six months. The relevant information related to the study objectives such as demographic details, type of medication, dose and frequency etc has been collected. The patient who has come for follow up during the study period has also been included to find out any outcomes RESULTS: Out of 30 patients included in the study, 63.3% were females and 36.7% were males. Most of the patients belong to the age group of 60-80 years. On prescription pattern analysis, it was found that 86.7% of the patients were on donepezil, cholinesterase inhibitors. Among antipsychotics Quetiapine was the most commonly used atypical antipsychotic. Five (16.7%) patients were on memantine where as 4 (13.3%) patients were on combination of donepezil and memantine. On follow up it was found that in three patients who was on donepezil has been changed to a combination of donepezil and memantine. Whereas in other two patients the dose of the donepezil has been increased. As a result of improvement seen in two patients donepezil was stopped and memantine was continued and in the other patient who has been on the combination of donepezil and memantine has been tapered gradually and stopped as there was a marked improvement seen. In this study, we could also find prescription error in 13.33% (4) of the prescription related to the overdose of donepezil CONCLUSIONS: In a developing country like India, dementia still remains as an underrecognized public health burden. Our study depicts a picture of usage of antidementia drugs, it shows that further research to be done in dementia patients related to cost effectiveness
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PMH79 THE IMPACT OF COMPARATIVE EFFECTIVENESS RESEARCH ON HEALTH AND HEALTH CARE SPENDING
Basu A 1 , Jena AB 2 , Philipson TJ 3 1 University of Washington, Seattle, WA, USA, 2 Massachusetts General Hospital, Boston, MA, USA, 3 University of Chicago, Chicago, IL, USA OBJECTIVES: Driven by rising costs of health care and concern that much of this spending could be reduced without detriment to health, comparative effectiveness research (CER) has been offered as a means to identify what works and does not work in health care. Little conceptual and empirical efforts have been made, however, to quantitatively assess the impact of CER on health and health care spending. We interpret CER as infusing publicly subsidized evidence on product quality into health care markets, shifting the relative demand for products in CER studies. We analyze how these shifts in demand affect health and health care spending, allowing for the possibility that "winners" of CER may be both more demanded by patients and doctors as well as more favorably covered by payers. We also analyze how CER may either raise or lower overall health when treatments have heterogeneous effects across patients, but payers respond with product-specific coverage policies. METHODS: We calibrate the effects of product-specific coverage policies for a major CER study for antipsychotics, the CATIE trial. RESULTS: We find that such policies would have led to a decrease in overall health and value by inducing some patients to switch away from treatments that were effective for them towards winners of the CER. CONCLUSIONS: Our overall conclusion is that CER may not always have the intended effects when the market responds to the CER and patient specific effects of treatments are present.
PMH81
COST-EFFECTIVENESS ANALYSIS OF ANTIDEPRESSANTS BY THE IQWIG IN GERMANY
Akmaz B, Kessel-Steffen M, Friede M, Weidenauer H, Flürenbrock W Lundbeck GmbH, Hamburg, Germany OBJECTIVES: German HTA-Agency (IQWIG) has published its preliminary report plan for Order G09-01 ЉCost-benefit analysis of venlafaxine, duloxetine, bupropion and mirtazapine in comparison to other prescription drug treatmentsЉ (version 1.0, updated 05-09-2011). This report plan provides important indicators, on how and to what extent innovative drugs are to be reimbursed by German statutory health insurances (SHI). METHODS: IQWIG conducts a cost-benefit analysis that can be divided into five steps with main focus on Mixed Treatment Comparison (MTC). The individual steps in the cost-benefit analysis are largely dependent upon one another, since the results of one step serve as the foundation for the next step of the analysis. It is critical to note that IQWIG compares the four individual antidepressants to active agent categories such as serotonin reuptake inhibitors (SSRIs), without having previously conducted a benefit analysis for these active agent groups. RESULTS: Preliminary report with the provisional assessments is expected in the 3rd quarter of 2011. At present, essential information and specifications of the methodical approach are still missing. Each of these steps yields considerable methodological challenges and can significantly influence the results of the costbenefit analysis. The MTC method, in particular, must be transparently described. Only in this manner, will it be possible to prevent uncertainties after every step from adding up to an invalid overall result. CONCLUSIONS: When MTC do not present relevant differences, or present them inadequately, this has significant effects on the assessment of therapeutic superiority, as well as on the appropriateness of the costs within the scope of the cost-benefit analysis. The result of such a cost-benefit analysis would be that the benefits and additional benefits of new drugs are levelled and the price level for modern antidepressants is decreased for Germany in future. LGMs were conducted to determine the level of variability in depression scores over the 12-year period. When considerable variability was identified, GMMs were conducted to assess whether there were subsets of individuals with differential changes. RESULTS:
PMH82 EXAMINING VARIABILITY IN DEPRESSION AMONG PRE-RETIREES: INNOVATIVE ANALYTIC METHODS APPLIED TO OBSERVATIONAL DATA
LGMs showed an intercept (first assessment point) score of 0.75 ("no depression") on the CES-D, which increased to 1.3 ("sub-threshold depression") at year 12. Substantial variability was found around the mean intercept and slope of change. GMMs identified three subsets of individuals with differential slopes of change. The largest subset (83% of the sample) had a mean intercept of 0.22 and a 12-year score of 1.0 ("no depression"). A smaller subset (13.7%) had a mean intercept of 2.5 and showed no change over the 12-year period ("stable, sub-threshold depressed"). The smallest subset (3.3%) had a high mean intercept (6.0) and showed a decrease in depression scores (4.0 at year 12; "improved, actively depressed"). Post hoc analyses showed that these three classes were significantly different in terms of gender, self-reported health, whether health limits their work or activities, and activities of daily living CONCLUSIONS: Examining highly variable data can yield insights about subsets of respondents who show different levels of initial depression and different trajectories of change.
PMH83 ESTIMATING UTILITIES IN SCHIZOPHRENIC AND BIPOLAR PATIENTS FROM DISEASE-SPECIFIC OR GENERIC INSTRUMENTS ASSESSING PATIENTS' HEALTH STATES: WHERE ARE THE DIFFERENCES?
Cuervo J 1 , Rebollo P 1 , Maurino J 2 , Cordero L 2 , Castejón N 1 1 BAP Health Outcomes Research, Oviedo, Spain, 2 AstraZeneca, Madrid, Spain OBJECTIVES: To compare the utility values estimated from a disease-specific instrument with those obtained from the EQ5D and SF6D in a sample of patients suffering from a psychotic disorder. METHODS: Data on patients diagnosed with schizophrenia or bipolar disorders was gathered in a multicentre, cross-sectional study. Patients completed both generic and specific measures: the TooL questionnaire, EQ-5D -VAS and TTO-, SF6D and the Clinical Global Impression -CGI-SI-. As it has been recently published, a multi-attribute utility function (MAUF) for the Spanish version of the TooL questionnaire was estimated. Differences in utility scores regarding CGI-SI-were tested with ANOVA and Kruskal-Wallis test. The Spearman correlation coefficient (rho), intraclass correlation coefficient and Wilcoxon rank test were calculated. Finally, the Bland-Altman method was followed for concordance assessment. RESULTS: In total, 37 patients with schizophrenia and 33 with bipolar disorder were assessed. Mean age (SD) was 41.88 (11.08), 62.9% were male and CGI-SI-was: borderline-mildly (50%), moderately (35.7%) and markedly-extremely ill (13.3%). Significant differences according to CGI-SI were found in all utility measures (pϽ0.05). Although all associations were high (rho range: 0.657-0.996), differences between the TooL scores and generic scales (SF6D and EQ5D; pϽ0.001) were found. Also between EQ5D and SF6D remarkable differences were found (pϽ0.001). Generic measures tended to overestimate at least 80% of health states in comparison to the TooL values. Finally, a low concordance was detected, even between generic measures. CONCLUSIONS: Although all measures of health values are highly associated, a low concordance has been evidenced. Utility values obtained from the TooL questionnaire could be used to complement the information from the EQ5D or SF6D. Finally, the specific measure could be even considered A301 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 -A 5 1 0
